Effects of long term sildenafil on the acute phase of Peyronie’s disease in a combination treatment

Abstract

Objectives: The aim of this study was to Summary investigate the impact of the addition of 50 mg daily sildenafil to pentoxifylline-colchicine combination therapy on the Peyronie's plaque features in patients with the acute phase of Peyronie's disease (PD). Methods: In this retrospective and non-randomized clinical study, patients were divided into 2 groups as group 1; (n = 107) who received colchicine and pentoxyfillin plus 50 mg daily oral sildenafil, and as group 2; (n = 79) who received only colchicine and pentoxyfillin. Patients were compared in terms of degree of curvature, pain in erection and erectile function at the baseline and at 6-month follow up. Pain in erection and erectile function were evaluated by visual Analogue Scale (EF-VAS), and the shortened version of the International Index of Erectile Function (IIEF-5). Improvement in the degree of curvature and change in EF-VAS scores were primary endpoints of the study. Change in IIEF-5 score was the secondary endpoint of the study. Results: The two groups were statistically similar in terms of demographics and baseline features of PD. A statistically significant reduction in degree of curvature and EF-VAS scores was shown in group 1 compared to group 2.There was also a significantly higher IIEF-5 score in group 1 compared to group 2. No significant side effects were detected in both groups during treatment period. Conclusions: Adding sildenafil to pentoxifylline-colchicine combination treatment seems to improve PD related symptoms in the acute phase PD. PDE5i may contribute to relieve the Peyronie's symptoms in ED patients through their antifibrotic effects.